We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-17.49%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$214M
AUM Growth
-$13.8M
(-6.1%)
Cap. Flow
+$50.8M
Cap. Flow
% of AUM
23.74%
Top 10 Holdings %
Top 10 Hldgs %
55.85%
Holding
56
New
18
Increased
15
Reduced
11
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$13.7M |
| 2 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$7.82M |
| 3 |
Cue Biopharma
CUE
|
+$6.7M |
| 4 |
Direxion Daily Small Cap Bear 3x ETF
TZA
|
+$6.06M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$5.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARQL
Arqule Inc
ARQL
|
+$8.99M |
| 2 |
United Therapeutics
UTHR
|
+$6.39M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$6.02M |
| 4 |
Zimmer Biomet
ZBH
|
+$3.38M |
| 5 |
Envista
NVST
|
+$2.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.8% |
| 2 | Miscellaneous | 4.08% |
| 3 | Technology | 2.61% |
| 4 | Energy | 2.29% |
| 5 | Industrials | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Organogenesis Holdings
ORGO
$224M
| $2.17M | 1.01% |
672,275
+54,439
| +9% | +$233K |
|
27
Evolus
EOLS
$587M
| $2.13M | 1% |
514,206
+277,267
| +117% | +$2.35M |
|
|
28
BioMarin Pharmaceuticals
BMRN
$12.5B
| $1.94M | 0.9% |
22,900
-69,837
| -75% | -$6.02M |
|
29
Immunovant
IMVT
$8.51B
| $1.89M | 0.88% |
121,429
-103,273
| -46% | -$1.55M |
|
30
Establishment Labs
ESTA
$2.11B
| $1.83M | 0.86% |
+126,658
| New | +$2.8M |
|
31
Gyre Therapeutics
GYRE
$699M
| $1.67M | 0.78% |
51,053
-1,200
| -2% | -$55.1K |
|
32
AbbVie
ABBV
$451B
| $1.22M | 0.57% |
+16,030
| New | +$1.37M |
|
33
AnaptysBio
ANAB
$1.67B
| $1.12M | 0.52% |
78,976
-155,847
| -66% | -$2.36M |
|
|
CHNG
34
CALL
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $999K | 0.47% |
+100,000
| New | +$1.4M |
|
|
35
Envista
NVST
$4.36B
| $867K | 0.41% |
58,000
-107,000
| -65% | -$2.74M |
|
36
Ligand Pharmaceuticals
LGND
$5.59B
| $836K | 0.39% |
+18,435
| New | +$1.04M |
|
37
HCA Healthcare
HCA
$90.5B
| $829K | 0.39% |
+9,223
| New | +$1.19M |
|
|
APEN
38
DELISTED
Apollo Endosurgery, Inc.
APEN
| $648K | 0.3% |
337,262
+177,926
| +112% | +$467K |
|
39
Insperity
NSP
$2.04B
| $481K | 0.22% |
+12,900
| New | +$915K |
|
|
KZR
40
DELISTED
Kezar Life Sciences
KZR
| $421K | 0.2% |
9,662
-22,338
| -70% | -$909K |
|
|
MITO
41
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
| $417K | 0.19% |
+336,167
| New | +$748K |
|
|
42
CALL
Evolus
EOLS
$587M
| $306K | 0.14% |
+73,700
| New | +$625K |
|
43
Tenet Healthcare
THC
$21.5B
| $301K | 0.14% |
+20,918
| New | +$600K |
|
44
Milestone Pharmaceuticals
MIST
$144M
| $77K | 0.04% |
41,592
+3,111
| +8% | +$53.9K |
|
|
ALLK
45
PUT
DELISTED
Allakos
ALLK
| – | – |
-20,700
| Closed | -$1.97M |
|
46
PUT
Axsome Therapeutics
AXSM
$10.4B
| – | – |
-6,000
| Closed | -$620K |
|
47
Bristol-Myers Squibb
BMY
$136B
| – | – |
-8,100
| Closed | -$520K |
|
48
Evolent Health
EVH
$520M
| – | – |
-279,390
| Closed | -$2.53M |
|
49
TriNet
TNET
$3.23B
| – | – |
-28,104
| Closed | -$1.59M |
|
|
RCM
50
DELISTED
R1 RCM Inc. Common Stock
RCM
| – | – |
-200,000
| Closed | -$2.6M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q1 2020 Portfolio in Review
As of Q1 2020, Prosight Management held 56 positions worth $214M, down 6.1% from $228M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Prosight Management deployed $50.8M of net new capital in Q1 2020, opening 18 new positions and adding to 15 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 140,000 shares worth $12.6M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was United Therapeutics, an estimated $6.39M trimmed.
- Prosight Management's largest Q1 2020 buy was Alexion Pharmaceuticals: 140,000 shares worth $12.6M.
- Prosight Management added most to Cue Biopharma in Q1 2020, an estimated $6.7M increase.
- Prosight Management's biggest Q1 2020 reduction was United Therapeutics, cutting an estimated $6.39M.
- Prosight Management fully exited Arqule Inc in Q1 2020, selling an estimated $8.99M.
- Prosight Management's ten largest holdings make up 56% of its $214M portfolio in Q1 2020.
- Prosight Management opened 18 new positions and closed 12 in Q1 2020.
- Prosight Management's portfolio value fell 6.1% quarter-over-quarter to $214M.
Based on Prosight Management's 13F filing for Q1 2020, filed 15 May 2020.